Ultragenyx Pharmaceutical Inc.
RARE
$39.34
$0.090.23%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 29.01% | 27.44% | 19.47% | 15.29% | 19.52% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 29.01% | 27.44% | 19.47% | 15.29% | 19.52% |
| Cost of Revenue | 8.81% | 96.38% | 35.54% | 36.65% | 39.53% |
| Gross Profit | 6.05% | -314.39% | -52.95% | -58.29% | -59.14% |
| SG&A Expenses | 3.81% | 3.31% | 3.25% | 8.29% | 11.38% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.24% | 5.53% | -4.23% | -2.59% | -0.87% |
| Operating Income | 5.84% | 9.62% | 18.42% | 12.90% | 12.28% |
| Income Before Tax | 6.72% | 11.62% | 17.88% | 13.77% | 13.29% |
| Income Tax Expenses | 187.51% | -589.67% | -128.68% | -133.11% | -132.04% |
| Earnings from Continuing Operations | 6.17% | 12.01% | 18.82% | 14.70% | 14.25% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 6.17% | 12.01% | 18.82% | 14.70% | 14.25% |
| EBIT | 5.84% | 9.62% | 18.42% | 12.90% | 12.28% |
| EBITDA | 7.87% | 12.10% | 20.96% | 14.87% | 13.87% |
| EPS Basic | 23.93% | 28.01% | 28.85% | 21.74% | 17.65% |
| Normalized Basic EPS | 24.47% | 27.39% | 28.03% | 19.24% | 14.40% |
| EPS Diluted | 23.87% | 27.96% | 28.80% | 21.69% | 17.65% |
| Normalized Diluted EPS | 24.47% | 27.39% | 28.03% | 19.24% | 14.40% |
| Average Basic Shares Outstanding | 23.12% | 22.75% | 14.98% | 9.79% | 5.15% |
| Average Diluted Shares Outstanding | 23.12% | 22.75% | 14.98% | 9.79% | 5.15% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
